Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Advantage Alpha Capital Partners LP

Advantage Alpha Capital Partners LP cut its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 34.8% during the third quarter, Holdings Channel reports. The firm owned 20,367 shares of the company’s stock after selling 10,891 shares during the quarter. Advantage Alpha Capital Partners LP’s holdings in Kiniksa Pharmaceuticals were worth $509,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. The Manufacturers Life Insurance Company purchased a new position in Kiniksa Pharmaceuticals in the 3rd quarter worth about $354,000. Algert Global LLC boosted its holdings in shares of Kiniksa Pharmaceuticals by 390.0% in the third quarter. Algert Global LLC now owns 91,159 shares of the company’s stock worth $2,278,000 after buying an additional 72,556 shares during the period. Cerity Partners LLC purchased a new position in shares of Kiniksa Pharmaceuticals in the third quarter worth approximately $834,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Kiniksa Pharmaceuticals by 40.2% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 324,064 shares of the company’s stock valued at $8,098,000 after acquiring an additional 92,985 shares during the period. Finally, Segall Bryant & Hamill LLC purchased a new stake in shares of Kiniksa Pharmaceuticals in the 3rd quarter valued at approximately $675,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on KNSA shares. JPMorgan Chase & Co. lifted their price objective on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Evercore ISI raised their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Finally, Jefferies Financial Group assumed coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 price target on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $36.60.

Kiniksa Pharmaceuticals Price Performance

Shares of NASDAQ:KNSA opened at $22.04 on Wednesday. The firm has a fifty day moving average of $24.23 and a two-hundred day moving average of $22.91. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $15.52 and a 12-month high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm had revenue of $112.21 million for the quarter, compared to analyst estimates of $111.51 million. During the same period in the previous year, the business posted ($0.20) EPS. Kiniksa Pharmaceuticals’s revenue for the quarter was up 67.4% on a year-over-year basis. On average, equities analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Insider Activity at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, insider John F. Paolini sold 60,692 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total value of $1,585,275.04. Following the completion of the sale, the insider now owns 52,038 shares of the company’s stock, valued at $1,359,232.56. The trade was a 53.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Eben Tessari sold 17,500 shares of the stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $24.99, for a total value of $437,325.00. Following the transaction, the chief operating officer now directly owns 116,975 shares in the company, valued at approximately $2,923,205.25. This represents a 13.01 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 95,192 shares of company stock valued at $2,479,390. 54.57% of the stock is owned by corporate insiders.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.